Experimentelle Studien zur Teratogenität von Valproinsäure

  • M. Radatz
  • Heinz Nau


Epidemiologische Studien belegen das erhöhte Missbildungsrisiko durch Valproinsäureeinnahme während der Schwangerschaft. Der teratogene Effekt ist dosisabhängig und von hoher Strukturspezifität. Untersuchungen am Tiermodell weisen auf einen chiralen rezeptor-ähnlichen Wirkungsort im Embryo. Valproinsäure interagiert mit bekannten Transkriptionsfaktoren und anderen Zielgenen während der Neuralrohrentwicklung. Der teratogene Mechanismus ist noch nicht aufgeklärt.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ardinger HH, Atkin JF, Blackston RD et al. (1988) Verification of the fetal valproate syndrome phenotype. Am J Med Genet 29:171–185PubMedCrossRefGoogle Scholar
  2. Aulthouse AL, Hitt DC(1994)The teratogenic effects of valproic acid in human chondrogenesis in vitro. Teratology 49: 208–217PubMedCrossRefGoogle Scholar
  3. Berezin V, Kawa A, Bojic U et al. (1996) Teratogenic potency of valproate analogues evaluated by quantitative estimation of cellular morphology in vitro. Toxic in Vitro 1o: 585–594CrossRefGoogle Scholar
  4. Bojic U, Elmazar MM, Hauck RS, Nau H (1996) Further branching of valproate-related carboxylic acids reduces the teratogenic activity, but not the anticonvulsant effect. Chem Res Toxicol 9: 866–870PubMedCrossRefGoogle Scholar
  5. Bojic U, Ehlers K, Ellerbeck U et al.(1998) Studies on the teratogen pharmacophore of valproic acid analogues: Evidence of interactions at a hydrophobic centre. Eur J Pharmacol 354: 289-299PubMedCrossRefGoogle Scholar
  6. Briner W, Lieske R(1995)Arnold-Chiari-like malformation associated with a valproate model of spina bifida in the rat. Teratology 52: 306–311PubMedCrossRefGoogle Scholar
  7. Bui LM, Taubeneck MW, Commisso JF, Uriu-Hare JY, Faber WD, Keen CL (1998) Altered zinc metabolism contributes to the developmental toxicity of 2- ethylhexanoic acid, 2-ethylhexanol and valproic acid. Toxicology 126: 9–21PubMedCrossRefGoogle Scholar
  8. Chen G, Yuan P, Hawver DB, Potter WZ, Manji HK (1997) Increase in AP-1 transcription factor DNA binding activity by valproic. Neuropsychopharmacology 16:238–245PubMedCrossRefGoogle Scholar
  9. Clarke DO, Brown NA (1987) Valproic acid teratogenesis and embryonic lipid metabolism. Arch Toxicol Suppl 11:143–147PubMedGoogle Scholar
  10. Clayton-Smith J, Donnai D(1995)Fetal valproate syndrome. J Med Genet 32: 724–727PubMedCrossRefGoogle Scholar
  11. Courage-Maguire C, Bacon CL, Nau H, Regan CM (1997) Correlation of in vitro anti-proliferative potential with in vivo teratogenicity in a series of valproate analogues [published erratum appears in Int J Dev Neurosci 1997 Jul15 (4–5):693–694]. Int J Dev Neurosci 15: 37–43PubMedCrossRefGoogle Scholar
  12. Daston GP, Baines D, Elmore E, Fitzgerald MP, Sharma S(1995)Evaluation of chick embryo neural retinal cell culture as a screen for developmental toxicants. Fundam Appl Toxicol 26: 203–210PubMedCrossRefGoogle Scholar
  13. Dencker L, Nau H, D’Argy R (1990) Marked accumulation of valproic acid in embryonic neu-roepithelium of the mouse during early organogenesis. Teratology 41: 699–706PubMedCrossRefGoogle Scholar
  14. DiLiberti JH, Farndon PA, Dennis NR, Curry CJ (1984) The fetal valpro ate syndrome. Am J Med Genet 19: 473–481PubMedCrossRefGoogle Scholar
  15. Ehlers K, Sturje H, Merker HJ, Nau H (1992) Valproic acid-induced spina bifida: A mouse model. Teratology 45.145–154PubMedCrossRefGoogle Scholar
  16. Elmazar MM, Hauck RS, Nau H (1993) Anticonvulsant and neurotoxic activities of twelve analogues of valproic acid. J Pharm Sci 82: 1255–1258PubMedCrossRefGoogle Scholar
  17. Elmazar MM, Nau H (1992) Methotrexate increases valproic acid-induced developmental toxi-city, in particular neural tube defects in mice. Teratog Carcinog Mutagen 12: 203–210PubMedCrossRefGoogle Scholar
  18. Elmazar MM, Nau H (1993) Trimethoprim potentiates valproic acid-induced neural tube defects (NTDs) in mice. Reprod Toxicol 7:249–254PubMedCrossRefGoogle Scholar
  19. Elmazar MM, Thiel R, Nau H (1992) Effect of supplementation with folinic acid, vitamin B6, and vitamin Biz on valproic acid-induced teratogenesis in mice. Fundam Appl Toxicol 18: 389–394PubMedCrossRefGoogle Scholar
  20. Finnell RH, Wlodarczyk BC, Craig JC, Piedrahita JA, Bennett GD (1997) Strain-dependent alterations in the expression of folate pathway genes following teratogenic exposure to valproic acid in a mouse model.. Am J Med Genet 7o: 303–311CrossRefGoogle Scholar
  21. Fowler B (1997) Disorders of homocysteine metabolism. J Inherit Metab Dis 20: 270–285PubMedCrossRefGoogle Scholar
  22. Harris C, Stark KL, Juchau MR (1988) Glutathione status and the incidence of neural tube defects elicited by direct acting teratogens in vitro. Teratology 37: 577–590PubMedCrossRefGoogle Scholar
  23. Hauck RS, Nau H (1989) Asymmetric synthesis and enantioselective teratogenicity of 2-n-propyl-4-pentenoic acid (4-en-VPA), an active metabolite of the anticonvulsant drug, valproic acid. Toxicol Lett z: 41–48Google Scholar
  24. Hauck RS, Nau H, Elmazar MM (1991) On the development of alternative antiepileptic drugs. Lack of enantioselectivity of the anticonvulsant activity, in contrast to teratogenicity, of 2-npropyl-4-pentenoic acid and 2-n-propyl-4-pentynoic acid, analogues of the anticonvulsant drug valproic acid. Naturwissenschaften 78: 272–274PubMedCrossRefGoogle Scholar
  25. Hendrickx AG, Nau H, Binkerd P, Rowland JM, Rowland JR, Cukierski MJ, Cukierski MA (1988) Valproic acid developmental toxicity and pharmacokinetics in the rhesus monkey: An interspecies comparison. Teratology 38: 329–345PubMedCrossRefGoogle Scholar
  26. Hishida R, Nau H (1998) VPA-induced neural tube defects in mice. I. Altered metabolism of sulfur amino acids and glutathione. Teratog Carcinog Mutagen 18: 49–61PubMedCrossRefGoogle Scholar
  27. Huot C, Gauthier M, Lebel M, Larbrisseau A (1987) Congenital malformations associated with maternal use of valproic acid. Can J Neurol Sci 14: 290–293PubMedGoogle Scholar
  28. Jäger-Roman E, Deichl A, Jakob S et al. (1986) Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. J Pediatr 108: 997–1004PubMedCrossRefGoogle Scholar
  29. Kliewer SA, Forman BM, Blumberg B et al.(1994)Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 91: 7355–7359PubMedCrossRefGoogle Scholar
  30. Klug S, Lewandowski C, Zappel F, Merker HJ, Nau H, Neubert D (1990) Effects of valproic acid, some of its metabolites and analogues on prenatal development of rats in vitro and comparison with effects in vivo. Arch Toxicol 64: 545–553PubMedCrossRefGoogle Scholar
  31. Lampen A, Göttlicher M, Siehler S, Ellerbeck U, Nau H (1998) A new molecular bioassay based on cell differentiation in vitro for the estimation of the teratogenic potency of valproic acid derivatives. Chemical Safety For The 21st Century. International Union of Toxicology, ParisGoogle Scholar
  32. Lindhout D, Schmidt D (1986) In-utero exposure to valproate and neural tube defects [letter]. Lancet 1: 1392–1393PubMedCrossRefGoogle Scholar
  33. Löscher W, Nau H (1985) Pharmacological evaluation of various metabolites and analogues of valproic acid. Anticonvulsant and toxic potencies in mice. Neuropharmacology 24: 427–435PubMedCrossRefGoogle Scholar
  34. Mino Y, Mizusawa H, Shiota K (1994) Effects of anticonvulsant drugs on fetal mouse palates cul-tured in vitro. Reprod Toxicol 8: 225–230PubMedCrossRefGoogle Scholar
  35. Nau H (1985) Teratogenic valproic acid concentrations: Infusion by implanted minipumps vs conventional injection regimen in the mouse. Toxicol Appl Pharmacol 80: 243–250PubMedCrossRefGoogle Scholar
  36. Nau H (1986 a) Transfer of valproic acid and its main active unsaturated metabolite to the gestational tissue: Correlation with neural tube defect formation in the mouse. Teratology 33: 21–27PubMedCrossRefGoogle Scholar
  37. Nau H (1986 b) Valproic acid teratogenicity in mice after various administration and phenobarbital-pretreatment regimens: The parent drug and not one of the metabolites assayed is implicated as teratogen. Fundam Appl Toxicol 6: 662–668PubMedCrossRefGoogle Scholar
  38. Nau H (1987) Valproinsäure - Serumkonzentrationen bei Monotherapie mit Einmal-, Zweimal-und Mehrfachgabe pro Tag. Nervenarzt 58: 459Google Scholar
  39. Nau H (1988) [Pharmacokinetic principles of the teratogenicity of drugs]. Internist (Berlin) 29: 179–192Google Scholar
  40. Nau H, Krauer B (1986) Serum protein binding of valproic acid in fetus-mother pairs throughout pregnancy: Correlation with oxytocin administration and albumin and free fatty acid concentrations. J Clin Pharmacol 26: 215–221PubMedGoogle Scholar
  41. Nau H, Löscher W (1986) Pharmacologic evaluation of various metabolites and analogs of valproic acid: Teratogenic potencies in mice. Fundam Appl Toxicol 6: 669–676PubMedCrossRefGoogle Scholar
  42. Nau H, Scott WJ (1986) Weak acids may act as teratogens by accumulating in the basic milieu of the early mammalian embryo. Nature 323: 276–278PubMedCrossRefGoogle Scholar
  43. Nau H, Rating D, Koch S, Hauser I, Helge H (1981) Valproic acid and its metabolites: Placental transfer, neonatal pharmacokinetics, transfer via mother’s milk and clinical status in neonates of epileptic mothers. J Pharmacol Exp Ther 219: 768–777PubMedGoogle Scholar
  44. Nau H, Hauck RS, Ehlers K (1991) Valproic acid-induced neural tube defects in mouse and human: Aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol Toxicol 69: 310–321PubMedCrossRefGoogle Scholar
  45. Nau H, Tzimas G, Mondry M, Plum C, Spohr HL(1995)Antiepileptic drugs alter endogenous retinoid concentrations: A possible mechanism of teratogenesis of anticonvulsant therapy. Life Sci 57: 53–60PubMedCrossRefGoogle Scholar
  46. Omtzigt JG, Los FJ, Grobbee DE et al. (1992) The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 42: 119–125PubMedGoogle Scholar
  47. Robert E (1988) Valproic acid as a human teratogen. Cong Anom 28: 71–80Google Scholar
  48. Robert E, Guibaud P (1982) Maternal valproic acid and congenital neural tube defects [letter]. Lancet 2: 937PubMedCrossRefGoogle Scholar
  49. Samren EB, van Duijn CM, Koch S et al. (1997) Maternal use of antiepileptic drugs and the risk of major congenital malformations: A joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 38: 981–990PubMedCrossRefGoogle Scholar
  50. Scott WJ, Schreiner CM, Nau H, Vorhees CV, Beliles RP, Colvin J, McCandless D (1997) Valproate-induced limb malformations in mice associated with reduction of intracellular pH. Re-prod Toxicol 11: 483–493CrossRefGoogle Scholar
  51. Sedowofia SK, Clayton RM (1985) Effects of anticonvulsant drugs on brain cultures from chick embryos: A comparison with cultures from embryos treated in ovo. Teratog Carcinog Muta-gen 5: 205–217CrossRefGoogle Scholar
  52. Trotz M, Wegner C, Nau H (1987) Valproic acid-induced neural tube defects: Reduction by folinic acid in the mouse. Life Sci 41: 103–110PubMedCrossRefGoogle Scholar
  53. Van der Put NM, Thomas CM, Eskes TK et al. (1997) Altered folate and vitamin B12 metabolism in families with spina bifida offspring. Q J Med 9o: 505–510Google Scholar
  54. Vorhees CV, Acuff-Smith KD, Weisenburger WP, Minck DR, Berry JS, Setchell KD, Nau H (1991) Lack of teratogenicity of trans-2-ene-valproic acid compared to valproic acid in rats. Teratology 43: 583–590PubMedCrossRefGoogle Scholar
  55. Vormann J, Höllriegel V, Merker HJ, Günther T (1986) Effect of valproate on zinc metabolism in fetal and maternal rats fed normal and zinc-deficient diets. Biol Trace Elern Res 10:25–35CrossRefGoogle Scholar
  56. Walmod PS, Foley A, Berezin A, Ellerbeck U, Nau H, Bock E, Berezin V (1998) Cell motility is inhibited by the antiepileptic compound, valproic acid and its teratogenic analogues. Cell Motil Cytoskeleton 4o: 220–237CrossRefGoogle Scholar
  57. Weber GF, Maertens P, Meng XZ, Pippenger CE (1991) Glutathione peroxidase deficiency and childhood seizures. Lancet 337:1443–1444PubMedCrossRefGoogle Scholar
  58. Wegner C, Nau H (1991) Diurnal variation of folate concentrations in mouse embryo and plasma: The protective effect of folinic acid on valproic-acid-induced teratogenicity is time dependent. Reprod Toxicol 5: 465–471PubMedCrossRefGoogle Scholar
  59. Wegner C, Nau H (1992) Alteration of embryonic folate metabolism by valproic acid during organogenesis: Implications for mechanism of teratogenesis. Neurology 42: 17–24PubMedGoogle Scholar
  60. Williams JA, Mann FM, Brown NA (1997) Gene expression domains as markers in developmen-tal toxicity studies using mammalian embryo culture. Int J Dev Biol 41: 359–364PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • M. Radatz
  • Heinz Nau

There are no affiliations available

Personalised recommendations